title: Premalignant lesions: diagnosis, evaluation, and management.
abstract: Acceptance and incorporation of widespread mammographic screening has led to an increase in the incidence of detection of "premalignant" breast lesions. Despite advances in our understanding of these diseases, their actual malignant potential remains somewhat unpredictable. Best current management of these diseases requires a multidisciplinary, coordinated approach between the disciplines of breast surgery, radiology, pathology, medical oncology, and radiation oncology at a minimum. Although this strategy has led to excellent outcomes, future advances in our understanding of the biologic determinants and behavior of these diseases will hopefully result in a more accurate assessment of the risk of progression to invasive breast cancer and allow us to individualize treatment more effectively.
authors.affiliation: The Warren Alpert School of Medicine of Brown University, Department of Obstetrics and Gynecology, Program in Women's Oncology, Women and Infants' Hospital, Providence, Rhode Island, USA. ttejadaberges@wihri.org
authors.forename: Trevor
authors.initials: T
authors.lastname: Tejada-Berges
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D018275:Carcinoma, Lobular / Q000453:epidemiology / Q000601:surgery; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008327:Mammography; D015412:Mastectomy, Segmental; D011230:Precancerous Conditions / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen